KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway - Oncogene
Nature
Last updated: April 29, 2026
This research investigates the role of the transcription factor KDM4B in small cell lung cancer (SCLC) and its association with chemotherapy resistance. The study analyzed expression profiles of transcription factors in SCLC cell lines to understand underlying mechanisms of drug resistance.
- Key Findings: The expression of four transcription factors was analyzed in 72 SCLC cell lines from the GDSC database, leading to the classification of nine SCLC subtypes.
- Higher expression of KDM4B was observed in SCLC cell lines exhibiting chemoresistance.
- Knockdown of KDM4B in resistant SCLC cells restored sensitivity to chemotherapy agents like cisplatin and etoposide.
- Conversely, overexpression of KDM4B in chemosensitive SCLC cells induced chemoresistance.
- KDM4B knockdown led to decreased expression of genes involved in DNA repair, such as RAD51 and γH2AX.
- This suggests that KDM4B promotes chemoresistance in SCLC by enhancing DNA repair mechanisms.
- The study identified KDM4B as a potential therapeutic target for overcoming chemotherapy resistance in SCLC.
